{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "N.D. (No transcript number provided in the literature to standardize HGVS nomenclature via API)",
          "cDNA Change": {
            "transcript": "N.D.",
            "ref": "N.D.",
            "alt": "N.D.",
            "position": "N.D."
          },
          "Protein Change": {
            "ref": "I",
            "alt": "T",
            "position": "2020"
          },
          "Description in input context": "I2020T"
        },
        {
          "HGVS": "N.D. (No transcript number provided in the literature to standardize HGVS nomenclature via API)",
          "cDNA Change": {
            "transcript": "N.D.",
            "ref": "N.D.",
            "alt": "N.D.",
            "position": "N.D."
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "G2019S"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005149"
  },
  "Experiment Method": [
    {
      "Assay Method": "Radiometric kinase activity assays",
      "Material used": {
        "Material Source": "Recombinant proteins",
        "Material Name": "N-terminal GST - tagged LRRK2 (amino acids 970 - 2527) wild - type, G2019S, and I2020T",
        "Description": "N - terminal GST - tagged LRRK2 (amino acids 970 - 2527) wild - type, G2019S, and I2020T were from Invitrogen Corporation."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "N.D. (HGVS not standardized due to lack of transcript number)",
          "Conclusion": "N.D.",
          "Molecular Effect": "N.D.",
          "Result Description": "Reaction rates were determined at various ATP concentrations to calculate specific activity (nmole/(min mg)) for wild - type, G2019S, and I2020T. The ATP K m,app value for G2019S (169 μM) was approximately 3 - fold higher than wild - type LRRK2 (51 μM), I2020T had a much lower ATP K m,app (7.5 ± 0.4 μM) and lower V max (44 nmol/(min mg)) than wild - type."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "No",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Kinase reactions were performed in duplicate."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Curve fitting and data analysis were performed with GraphPad Prism software to fit the Michaelis - Menten equation to the data."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D. (Based on knowledge, normal kinase activity can be considered as values similar to wild - type under the same experimental conditions)",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D. (Based on knowledge, abnormal kinase activity can be considered as values significantly different from wild - type under the same experimental conditions)",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "TR - FRET kinase activity assays",
      "Material used": {
        "Material Source": "Recombinant proteins",
        "Material Name": "N - terminal GST - tagged LRRK2 (amino acids 970 - 2527) wild - type, G2019S, and I2020T",
        "Description": "N - terminal GST - tagged LRRK2 (amino acids 970 - 2527) wild - type, G2019S, and I2020T were from Invitrogen Corporation."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "N.D. (HGVS not standardized due to lack of transcript number)",
          "Conclusion": "N.D.",
          "Molecular Effect": "N.D.",
          "Result Description": "IC 50 values for sunitinib were determined. At ATP K m,app , IC 50 values for sunitinib were similar for all LRRK2 variants: 71, 74, and 75 μM for wild - type, G2019S, and I2020T, respectively. At 1 mM ATP, wild - type LRRK2 had an IC 50 of 370 nM, I2020T was incompletely inhibited with an IC 50 value of at least 5 μM, and G2019S had an IC 50 value of 230 nM."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "No",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "All assays were performed using either three or four replicates for each data point represented."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D. (Based on knowledge, normal inhibitor sensitivity can be considered as values similar to wild - type under the same experimental conditions)",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D. (Based on knowledge, abnormal inhibitor sensitivity can be considered as values significantly different from wild - type under the same experimental conditions)",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "TR - FRET binding assays",
      "Material used": {
        "Material Source": "Recombinant proteins",
        "Material Name": "N - terminal GST - tagged LRRK2 (amino acids 970 - 2527) wild - type, G2019S, and I2020T",
        "Description": "N - terminal GST - tagged LRRK2 (amino acids 970 - 2527) wild - type, G2019S, and I2020T were from Invitrogen Corporation."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "N.D. (HGVS not standardized due to lack of transcript number)",
          "Conclusion": "N.D.",
          "Molecular Effect": "N.D.",
          "Result Description": "The affinities were 39 ± 1, 4.5 ± 1, and 75 ± 1 μM for wild - type, I2020T, and G2019S, respectively. I2020T has an approximately 9 - fold higher affinity for ATP, and the ATP affinity of G2019S is about 2 - fold lower than wild - type LRRK2."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "No",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D. (Based on knowledge, normal ATP affinity can be considered as values similar to wild - type under the same experimental conditions)",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D. (Based on knowledge, abnormal ATP affinity can be considered as values significantly different from wild - type under the same experimental conditions)",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}